VRCA — Verrica Pharmaceuticals Inc.

Summary of Verrica Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $14.3 million, a significant increase from a negative revenue of $1.8 million in Q3 2024.
  • Collaboration Revenue: $10.7 million from Torii Pharmaceuticals.
  • Net YCANTH Revenue: $3.6 million, up from $84,000 in Q3 2024.
• Gross Product Margins: 79.1%.
• GAAP Net Loss: $0.2 million ($0.03 per share), a substantial improvement from a loss of $22.9 million ($4.88 per share) in Q3 2024.
• Non-GAAP Net Income: $1.2 million ($0.13 per share), compared to a net loss of $20.2 million ($4.30 per share) in the prior year.
• Cash Position: $21.1 million as of September 30, 2025, bolstered by $18 million in milestone payments from Torii.

2. Strategic Updates and Business Highlights

• YCANTH Growth: Continued adoption with a 5% quarter-over-quarter growth in dispensed applicator units. Total units dispensed reached 37,642 for the first nine months of 2025, a 120% increase year-over-year.
• Phase III Programs: Initiation of Phase III clinical trials for YCANTH in common warts, with first patient dosing expected in December 2025. Positive FDA feedback received for the oncology asset VP-315 for basal cell carcinoma.
• New Initiatives: Launch of YCANTH Rx, a non-dispensing pharmacy aimed at simplifying prescription processes for providers and patients, expected to enhance patient access and speed to therapy.
• Sales Force Expansion: Increased from 45 to 50 sales representatives planned for 2026 to enhance market penetration.

3. Forward Guidance and Outlook

• Anticipation of continued growth in YCANTH sales, with expectations of strong organic growth as the product establishes itself as a leading therapy.
• Filing for YCANTH’s Marketing Authorization Application in the EU expected by Q4 2026, with no additional Phase III studies required.
• Ongoing exploration of strategic partnerships to support development and commercialization of pipeline assets.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Anticipated traditional slowdowns in sales during November and December due to holidays, which could affect Q4 revenue.
• Competitive Pressures: The primary competitor remains the "watch and wait" approach, with Zelsuvmi's launch introducing additional market dynamics that require strategic adjustments.
• Operational Risks: The need to secure a pediatric waiver in the EU adds complexity and time to the approval process, potentially delaying market entry.

5. Notable Q&A Insights

• Q4 Sales Demand: Management noted that momentum from September is continuing into Q4, but acknowledged potential seasonal slowdowns.
• Sales Force Productivity: New hires expected to ramp up productivity early in 2026, with a focus on both expanding existing prescriber engagement and reaching new markets.
• YCANTH Rx Feedback: Positive initial feedback from key opinion leaders regarding the new pharmacy model, aimed at simplifying the prescription process for clinicians.
• Metrics for YCANTH Rx: While specific KPIs were not disclosed, management indicated they would track time to fill and the number of prescriptions fulfilled.

Overall, Verrica Pharmaceuticals demonstrated significant financial improvement and strategic progress in Q3 2025, while also acknowledging challenges related to seasonality and competition. The company remains optimistic about future growth driven by its product pipeline and strategic initiatives.